What 6 Analyst Ratings Have To Say About DexCom

DexCom DXCM underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $98.83, along with a high estimate of $115.00 and a low estimate of $82.00. This upward trend is evident, with the current average reflecting a 10.8% increase from the previous average price target of $89.20.

Investigating Analyst Ratings: An Elaborate Study

An in-depth analysis of recent analyst actions unveils how financial experts perceive DexCom. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

| Analyst | Analyst Firm | Action Taken | Rating |Current Price Target| Prior Price Target | |--------------------|--------------------|---------------|---------------|--------------------|--------------------| |Anthony Petrone |Mizuho |Announces |Outperform | $85.00|- | |Joanne Wuensch |Citigroup |Raises |Buy | $104.00|$101.00 | |William Plovanic |Canaccord Genuity |Raises |Buy | $103.00|$99.00 | |Patrick Wood |Morgan Stanley |Raises |Equal-Weight | $82.00|$75.00 | |Issie Kirby |Redburn Atlantic |Raises |Buy | $115.00|$85.00 | |Jeff Johnson |Baird |Raises |Outperform | $104.00|$86.00 |

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to DexCom. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DexCom compared to the broader market.
• Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of DexCom's stock. This examination reveals shifts in analysts' expectations over time.

Capture valuable insights into DexCom's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on DexCom analyst ratings.

All You Need to Know About DexCom

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

DexCom: Delving into Financials

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Revenue Growth: DexCom's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 7.64%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 13.62%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): DexCom's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.43% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): DexCom's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.36% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: DexCom's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.23, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

What Are Analyst Ratings?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.